Reported Characteristics of Anaphylaxis Associated With Glatiramer Acetate: A Pharmacovigilance Analysis of the FDA and Canadian Databases
Pharmacology Research & Perspectives · 2026-08 · 14 (4)
DOI: 10.1002/prp2.70303 ↗Kurz gefasst
Fachartikel in der Zeitschrift Pharmacology Research & Perspectives, online erschienen am 31.07.2026. Verfasst von Tailei Nie und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacy, Affiliated Hospital of Yangzhou University, Yangzhou University, Yangzhou, Jiangsu, China. Hauptthemen laut MEDLINE: Anaphylaxis, Glatiramer Acetate, Immunosuppressive Agents. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 28 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
The FDA has mandated a Boxed Warning for glatiramer acetate (GA) due to the risk of serious anaphylactic reaction. This study aimed to characterize the reported features of GA‐associated anaphylaxis. Data mining was performed using the Reporting Odds Ratio (ROR) in the FDA Adverse Event Reporting System (FAERS) database (Q1 2004–Q1 2025) and the Canadian Vigilance Adverse Reaction (CVAR) database (Q1 1996–Q1 2025). Demographic characteristics, time‐to‐onset (TTO), and case seriousness were compared using the Mann–Whitney U test or the Chi‐squared ( χ 2 ) test. In the FAERS database, 9816 reports were identified with 29 significant disproportionality signals. Younger age ( p < 0.01) was significantly associated with a higher proportion of serious reports. The association between GA and anaphylactic AEs remained statistically significant after stratification by age, body weight, sex, and reporter types. Twenty AEs demonstrated significantly higher reporting rates in serious cases ( p < 0.05). Clinical prioritization identified 9 moderate‐priority and 20 weak‐priority signals. The median TTO was 197 days for moderate‐priority signals versus 153 days for weak‐priority signals. All signals exhibited early failure‐type patterns, indicating that reported anaphylactic events were more frequently observed earlier after treatment initiation than later in treatment. In the CVAR database, 711 reports were identified. A total of 17 PTs overlapped with FAERS, with respiratory arrest uniquely present in CVAR. Three PTs were rated as moderate priority in the CVAR database but weak priority in FAERS. This large‐scale pharmacovigilance analysis of the FDA and Canadian databases characterizes the safety signals derived from GA‐associated reports of anaphylaxis, providing a hypothesis‐generating foundation for future pharmacovigilance validation.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pharmacy, Affiliated Hospital of Yangzhou University, Yangzhou University, Yangzhou, Jiangsu, China.
- Department of Biomedical Engineering, Columbia University, New York, New York, USA.
- School of Biomedical Sciences and Engineering, South China University of Technology, Guangzhou, Guangdong, China.
- Department of Pharmaceutics, School of Pharmacy, China Pharmaceutical University, Nanjing, China.
ORCID-Profile: Tailei Nie, Chuanxu Cheng, Jiajing Lu
Zitieren
APA
Nie, T., Liu, H., Cheng, C., Li, J., & Lu, J. (2026). Reported Characteristics of Anaphylaxis Associated With Glatiramer Acetate: A Pharmacovigilance Analysis of the FDA and Canadian Databases. Pharmacology Research & Perspectives, 14(4). https://doi.org/10.1002/prp2.70303
Vancouver
Nie T, Liu H, Cheng C, Li J, Lu J. Reported Characteristics of Anaphylaxis Associated With Glatiramer Acetate: A Pharmacovigilance Analysis of the FDA and Canadian Databases. Pharmacology Research & Perspectives. 2026;14(4). doi:10.1002/prp2.70303
BibTeX
@article{Nie2026,
author = {Nie, Tailei and Liu, Hongyu and Cheng, Chuanxu and Li, Jian and Lu, Jiajing},
title = {Reported Characteristics of Anaphylaxis Associated With Glatiramer Acetate: A Pharmacovigilance Analysis of the FDA and Canadian Databases},
journal = {Pharmacology Research & Perspectives},
year = {2026},
volume = {14},
number = {4},
doi = {10.1002/prp2.70303}
}
EUVIMED